BlossomHill Therapeutics (NASDAQ:BLSM) Stock Lifted to Hold by Wall Street Zen

Wall Street Zen upgraded shares of BlossomHill Therapeutics (NASDAQ:BLSM) from a sell rating to a hold rating in a report published on Saturday morning,Wall Street Zen reports.

Other equities research analysts also recently issued reports about the stock. Lifesci Capital started coverage on shares of BlossomHill Therapeutics in a research report on Tuesday, September 1st. They issued an “outperform” rating and a $32.00 price objective for the company. Leerink Partners increased their target price on shares of BlossomHill Therapeutics from $36.00 to $40.00 and gave the stock an “outperform” rating in a research report on Monday, September 21st. Zacks Research raised BlossomHill Therapeutics to a “hold” rating in a report on Wednesday, September 2nd. Guggenheim boosted their price target on shares of BlossomHill Therapeutics from $30.00 to $40.00 and gave the company a “buy” rating in a research report on Monday, September 21st. Finally, HC Wainwright reissued a “buy” rating on shares of BlossomHill Therapeutics in a research note on Wednesday, September 30th. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $35.00.

BlossomHill Therapeutics Stock Down 7.5%

Shares of BLSM opened at $14.63 on Friday. The business’s 50-day moving average is $19.16. BlossomHill Therapeutics has a 1 year low of $12.93 and a 1 year high of $27.99. The company has a market capitalization of $464.94 million and a P/E ratio of -1.67.

BlossomHill Therapeutics (NASDAQ:BLSM) last released its earnings results on Friday, September 18th. The company reported ($8.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($7.91). On average, research analysts predict that BlossomHill Therapeutics will post -5.54 EPS for the current fiscal year.

Insider Transactions at BlossomHill Therapeutics

In other BlossomHill Therapeutics news, Director Orbimed Advisors Llc bought 625,000 shares of the stock in a transaction dated Monday, August 10th. The stock was purchased at an average cost of $16.00 per share, for a total transaction of $10,000,000.00. Following the completion of the acquisition, the director owned 2,714,279 shares of the company’s stock, valued at approximately $43,428,464. This trade represents a 29.91% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director John P. Schmid acquired 6,000 shares of the stock in a transaction on Monday, August 10th. The shares were bought at an average price of $16.00 per share, with a total value of $96,000.00. Following the purchase, the director directly owned 6,000 shares of the company’s stock, valued at $96,000. The trade was a ? increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have purchased 1,573,900 shares of company stock worth $25,181,900.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.